SCHMID Group N.V. Reports Mixed H1 2026 Results, Cuts EBITDA Guidance

  • SCHMID Group N.V. reported H1 2026 revenues of €46.0 million, up from €16.9 million in the same period last year, with China contributing over half of the revenues.
  • Adjusted EBITDA improved to €-0.6 million from €-11.6 million year-over-year, but gross margin was lower than anticipated at 21.2% due to a product mix shift towards lower-margin business in China.
  • Order intake surged to €96.6 million year-to-date as of August 21, 2026, with a backlog of €95.0 million, prompting the company to raise its full-year order intake guidance to the upper half of €125–150 million.
  • The company reduced financial debt by close to €30 million between December 31, 2025, and June 30, 2026, and raised €20.0 million through a new 2029 Convertible Notes offering in July 2026.
  • Full-year 2026 Adjusted EBITDA margin guidance was lowered to 6 to 9% from the previous expectation of more than 12%.

SCHMID Group N.V. is navigating a transition year marked by significant restructuring and operational groundwork. The company's focus on cost reduction and deleveraging comes amid a surge in order intake, particularly in China. However, its lowered EBITDA guidance highlights the challenges of balancing growth with profitability in a competitive semiconductor and electronics manufacturing landscape. The strategic shift towards China and the planned expansion of its manufacturing capacity there will be critical to its long-term success.

Execution Risk
Whether SCHMID can sustain its order momentum and improve margins in H2 2026, particularly as it implements its 'Sprint II' purchasing cost reduction program.
Geographic Shifts
How the company's increasing reliance on China for revenue will impact its overall financial performance and strategic positioning.
Financial Flexibility
The pace at which SCHMID can reduce its debt and improve its cash position, given its recent financing activities and upcoming capital expenditures for its new Chinese manufacturing campus.